INTRODUCTION
STATISTICAL ISSUES FOR multiplicity have gained increasing importance in clinical trials since it is often difficult to focus on only one primary variable. For example, antiinflammatory treatment of chronic asthma should improve both the pulmonary function and the subjective outcomes reported by the patients.
There are some global assessment measures, for example, methods based on ordinary and generalized least squares which were proposed by O'Brien (1). Unfortunately, these global measures do not provide specific information on the variables contributing to the possibly significant difference. A closed testing procedure, however, can be applied to O'Brien's method (2,3), but the tests concerning single endpoints may not be significant although there is a global significance. Moreover, according to Zhang et al. (4) , O'Brien's approach is powerful when all variables have similar treatment effect sizes, but even the Bonferroni adjustment is more powerful if one variable has a very small effect while another has a much larger effect. In the case of asthma trials there are differences in the effect sizes between different endpoints; this is described in the section called "Examples."
The authors consider the situation where the endpoints can be classified into different groups and that the clinical objetive is to show at least one positive effect in each group. A suggestion for the handling of multiple endpoints in the evaluation of asthma trials was given by Capizzi and Zhang (5), whose approach is presented next. A modified approach is introduced and compared with a Bonferroni-type and a Simes-type adjustment. The methods are applied to two clinical trials. Then the results are discussed and a further extension presented.
EVALUATION OF MULTIPLE ENDPOINTS
Decision Rules According to Capizzi and Zhang (5) In the following, the suggestions of Capizzi and B a n g ( 5 ) for the evaluation of placebocontrolled asthma trials with multiple endpoints are described. There are four primary endpoints: the forced expiratory volume in one second (FEV,), the peak expiratory flow rate (PEF), asthma-specific symptom scores, and the use of rescue medication. The endpoints can be classified into two groups: Pulmonary function: FEV, and PEF, and Patient recorded outcomes: symptom scores and use of rescue medication. All four endpoints are considered to be sensitive measures of the treatment effect.
Capizzi and Zhang (5, p. 954) provided two decision rules:
Capizzi and ZhangS rule 1: In each group, one endpoint must be significant at the 0.05 level and the other endpoint has to trend in the right direction, that is, the other endpoint must be significant at the 0.2 level, and Capiui and Zhung 's rule 2: In each group, one endpoint must be significant at the 0.05 level and the other endpoint has to trend in the right direction, that is, the other endpoint must be significant at the 0.1 level.
According to Capizzi and Zhang (3, the objective is to show a positive effect in each of these four endpoints, that is, the statistical alternative is that there are treatment differences concerning all four endpoints.
Nevertheless, Capizzi and Zhang ( 5 ) considered the null hypothesis "no treatment effect"; therefore, they do not cover the entire parameter space. In Capizzi and Zhang's opinion, this is reasonable in placebo-controlled Phase IIbAII clinical trials. The authors cannot agree with this point of view.
The complete complement of the alternative "treatment differences concerning all four endpoints" is "no effect concerning at least one endpoint." For example, when three endpoints show very strong effects and one endpoint shows no effect, this constellation is an element of the complement, that is, the null hypothesis. However, in this constellation both rules would lead to significant results with more than 5% probability. Consequently, both rules do not control the experimentwise type I error rate when the complete complement of the alternative is considered as a null hypothesis. An appropriate level-a test would be the intersectionunion test (6) . An intersection-union test leads to a significant result, if every single endpoint is significant with regard to the unadjusted a-level.
Proposed Methods
As mentioned in the introduction, the antiinflammatory treatment of chronic asthma should improve both the pulmonary function and the subjective outcomes reported by patients. Hence, the clinical objective is to show at least one positive effect in each group, that is, one considers the alternative that there is a treatment effect concerning at least one endpoint in each group. The null hypothesis is that there is no effect in at least one group.
According to the intersection-union principle, one needs a level-a test for each group. Three methods are considered. The first one is a combination of the intersection-union principle with a within-group Bonferroni adjustment: Method I: In each group, at least one endpoint must be significant at the 0.025 level.
The endpoints, however, are correlated, especially within the two groups, and, consequently, a Bonferroni-type adjustment can be very conservative. Simes (7) suggested an adjustment which is more powerful than a Bonferroni adjustment. Let P(,) I P(*) I . . . I P(r, be the ordered P-values of r tests. Accordapproach, however, is not considered in this paper.
The Size and Power of the Proposed Methods
According to the intersection-union princiing to simes (7) Figure 1 presents the size of the three methods; the actual size within one group of method controls the tYp I error rate when the are investigated within the groups, that is, the type I error rate for positive dependence. For some other multi-significant at the 0.025 level or both endtion, a simulation of sarkar and Chmg endpoint must be significant at the 0.1 level.
tion-union principle with a within-group Simes adjustment: Merhod 2: In each group, endpoints is displayed. All methods lead to 1evel-a tests. Method 2 is less conservative at least one endpoint must be significant at than Method since the rejection region of the 0.025 level or both endpoints must be the Simes contains that of he Bansignificant at the 0.05 level. In addition, an-ferroni method. Method is conservaother method, which is similar to the rule 2 tive than the other in caSeS of low of Capizzi and Zhmg (3, is investigated. In correlations between the endpoints and utinull hypothesis that there is no effect in at only in of very high correlations. Other least one group, one must use a lower bound sample sizes lead to than 0.05: The power of the methods is investigated endpoint must be significant at the 0.04 level and the other endpoint has to trend in the right direction, that is, the other endpoint must be significant at the 0.1 level. These three methods are investigated with respect to size and power in the following. It should be noted that instead of the Bonferroni and Simes adjustment, respectively, the Westfall and Young (1 1) methods could be used. This order to control the ~Y F I error rate for the lizes the a-level in a more complete way CUNeS.
Method 3 states that:
In each group, one for the following correlation structure:
That is, the correlation between the endpoints within a group is pI and the correlation be- tween any two endpoints of different groups is p2. In a simulation study, which has been performed with SAS version 6.09 (1 3), a vector of correlated standard normal random variables was created according to Bratley et al. (14) . Again, a parallel-group design with a placebo and a treatment arm with 50 patients each is considered. In the treatment arm, the location of the simulated standard normally distributed variables were shifted. For all four endpoints, univariate two-sided Student's t tests were performed. Table 1 contains representative simulation results. For each combination of parameters, 10,000 simulation runs were generated. According to these results Method 2 (in each group using the Simes adjustment) should be preferred to the other methods. Method 2 is always at least as powerful as Method 1 (in each group using the Bonferroni adjustment). Method 2 is much more powerful than Method 3 (in each group 0.04 for one and 0.1 for the other endpoint) if there is no effect concerning at least one out of the four endpoints. According to further simulations with sample sizes of 25 and 100 per group, respectively, these conclusions also hold for other sample sizes (results not shown). As a further example a randomized, multicenter, double-blind, parallel design clinical trial which was designed to examine the efficacy of budesonide 400 pg twice daily with added theophylline compared to bude- sonide 800 pg twice daily in asthmatic patients (15) is considered. In each group 3 1 patients completed the study. The correlation between the endpoints is displayed in Table 2 .
EXAMPLES
The within-group correlation is much higher than the correlation among endpoints from different groups. Therefore, the motivation for the classification of the endpoints is satisfied.
Although this is an active-controlled study, there was a benefit among the theophylline treated group for FEV, (P,wo-s,u= 0.0275). For PEF a two-sided P-value of 0.1629 was obtained. As for the above-mentioned placebo-controlled trial, however, the P-values of the patient-recorded outcomes are much larger and failed to show a significant difference in this active-controlled study. Hence, none of the methods leads to a significant result. Active-controlled studies, however, are often conducted in order to show noninferiority or equivalence between treatments as was the case in this second example, and other statistical methods, for example, one-sided tests for noninferiority, are appropriate. In this active-controlled study, the noninferiority of the theophyllinetreated group was statistically proven; these results and methodical issues for equivalence tests are presented by Steinijans et al. (16) .
DISCUSSION
As demonstrated in the last section, the proposed methods may not be applicable in active-controlled studies. This was also mentioned by Capizzi and Zhang ( 5 ) for their decision rules. In placebo-controlled asthma trials, however, there is a further important Steroid-naive asthma patients are rarely available; therefore, in placebo-controlled trials a randomized subset of patients is switched from the previous therapy to placebo, and premature drop-out due to lack of efficacy is to be expected. Wolfe et al. (17) and Chervinsky et al. (1 8) reported drop-out rates due to lack of efficacy of 72% and 63%, respectively, in the placebo arm, but lower drop-out rates ranging from 4% to 23% in the different dose groups. Therefore, the drop-out rate due to predefined lack of efficacy criteria and the time-course of dropouts can provide a discriminative endpoint.
The drop-out rate cannot be included in one of the two groups of endpoints and, hence, represents a new variable group. Consequently, according to the intersectionunion principle one can additionally demand that the drop-out rate due to lack of efficacy is significant at the unadjusted level a.
In comparison with lung function variables such as FEV, and PEF, however, the drop-out rates due to lack of efficacy may have greater power to discriminate between treatments. Therefore, the drop-out rate is considered to be the most important endpoint by some investigators and regulatory bodies. Consequently, one can use the principle of a priori ordered hypotheses (19, 20, 21) in the following way. The first test is a logrank test concerning the drop-out times at the full a-level, for example, 5%. If and only if this test is significant, the other endpoints will be tested according to the methods described above. It should be noted, however, that high drqp-out rates may make other endpoints difficult to evaluate and may lead to lack of comparability of the treatment groups for the other endpoints.
In the placebo-controlled fluticasone studies reported by Wolfe et al. (17) and Chervinsky et al. (1 8 ) the drop-out rates due to lack of efficacy were highly significant (PIO.001 in both studies). The use of ordered hypotheses has the advantage that a significance concerning the drop-out rate can be proven without the need to demonstrate significant effects of the other variables.
